Q2 2026 was the quarter when the largest cannabis companies stopped bleeding. Curaleaf, Green Thumb, and Cresco Labs all posted positive net income, driven by Schedule III tax relief, aggressive cost-cutting, and retail execution — not by rising prices, which kept falling almost everywhere. Here's what the numbers mean if you run one store, not one hundred.
How did the big operators actually perform?
Better than the stock charts suggest — and the profit came from operations and taxes, not growth.
Curaleaf posted $340 million in revenue, up 10% year over year, with a 50% gross margin and net income of $12.5 million — a $60 million swing from last year's loss. A $38.8 million tax benefit tied to the federal reclassification of medical cannabis to Schedule III did much of the lifting, and a new $35–40 million SG&A cost-reduction program is coming behind it.
Green Thumb delivered $307 million in revenue (up 5%) and $4.9 million in net income, with a 28% EBITDA margin and $284 million in cash. The caution flag: same-store sales fell 1% across its 103 stores, and gross margin dropped from 50% to 45%.
Trulieve reported $271 million in revenue and a headline $406 million net loss — but that was a one-time, non-cash charge from spinning off its Harvest adult-use operations. The real story: Trulieve is now a pure-play medical operator with a 63% gross margin on medical-only revenue, a 36% adjusted EBITDA margin (the industry's best), and it became the first U.S. cannabis company listed on the NYSE.
Verano grew revenue 8% to $218 million with a 46% gross margin. Still unprofitable — a $13.4 million net loss — but narrowing, with operating cash flow nearly tripling year over year to $31 million.
Cresco Labs grew revenue 15% sequentially to $173 million and posted $16.8 million in net income. Its standout stat: the nine Pennsylvania dispensaries it acquired improved gross profit dollars by 11% in the first quarter of ownership — before rebranding a single store.
What should independent dispensaries take from this?
Three lessons, all replicable without MSO scale.
Margin lives in loyalty, not price: Curaleaf's leadership was explicit on its earnings call that the strategy is building brand stickiness so customers return for the product, not the discount. Trulieve generates 94% of revenue from retail at a 60% blended gross margin. The operators winning on margin are competing on experience and repeat visits — a game independents can play better than anyone.
The 280E moment is now: Curaleaf's $38.8 million tax benefit came directly from the April Schedule III reclassification of state-licensed medical cannabis, and Trulieve registered all of its state-licensed medical facilities with the DEA within the quarter. If any of your revenue touches a state medical license, sit down with your CPA this month and model your 280E relief scenarios. The MSOs already have.
Operations beat acquisitions: Cresco's 11% gross-profit improvement at acquired Pennsylvania stores came from merchandising, assortment, and store-level execution — not capital. That's the cheapest profit available to any operator, at any size.
Where are the warning signs?
Price compression isn't done, and the second half looks harder than the first.
Green Thumb's negative same-store sales show that even top-tier retail is fighting for flat traffic in mature markets. Cresco guided gross margins down to the high-40s for the back half of the year and flagged intensifying vertical integration in Illinois — MSOs opening their own stores in markets where they used to be your wholesale partners. Curaleaf expects only low single-digit sequential growth in Q3, citing seasonality in Florida and Arizona and ongoing declines in Arizona and Illinois. And watch the adjusted-EBITDA mirage: Verano posts a 24% adjusted EBITDA margin and still loses money under GAAP. If your own books rely on add-backs to look healthy, the market is telling you that isn't enough anymore.
The growth, meanwhile, is concentrated in newer limited-license markets — Georgia, Kentucky, Virginia, Texas, Pennsylvania. If you operate in a mature market, the plan for 2027 is margin defense, not expansion.
FAQ
Did Schedule III actually improve cannabis company profits? Yes, materially. Curaleaf booked a $38.8 million tax benefit in Q2 tied to the reclassification of state-licensed medical cannabis, and it was the single largest driver of its swing to net income. Full rescheduling of all marijuana is still pending after the DEA's summer hearing.
Which cannabis company was most profitable in Q2 2026? By margin, Trulieve: a 36% adjusted EBITDA margin and 63% gross margin on medical-only operations. By GAAP net income, Cresco Labs' $16.8 million led on a percentage-of-revenue basis.
Is cannabis price compression getting better or worse? Persisting. Green Thumb, Cresco, and Curaleaf all cited continued pricing pressure, with some easing in select markets but margin guidance moving down, not up, for the second half of 2026.